IDEXX Laboratories (IDXX) 10-Q 28 Apr 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 25, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Registrant Name	IDEXX LABORATORIES INC /DE
Entity Central Index Key	874,716
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		88,123,451

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 160,408	$ 154,901
Marketable securities	239,933	236,949
Accounts receivable, net of reserves of $4,909 in 2017 and $4,523 in 2016	225,353	204,494
Inventories	172,183	158,034
Other current assets	80,711	91,206
Total current assets	878,588	845,584
Long-Term Assets:
Property and equipment, net	361,233	357,422
Goodwill	180,601	178,228
Intangible assets, net	45,686	46,155
Other long-term assets	105,983	103,315
Total long-term assets	693,503	685,120
TOTAL ASSETS	1,572,091	1,530,704
Current Liabilities:
Accounts payable	62,249	60,057
Accrued liabilities	174,763	236,131
Line of credit	671,000	611,000
Current portion of deferred revenue	28,065	27,380
Total current liabilities	936,077	934,568
Long-Term Liabilities:
Deferred income tax liabilities	39,964	39,287
Long-term debt	594,868	593,110
Long-term deferred revenue, net of current portion	33,074	33,015
Other long-term liabilities	42,020	38,937
Total long-term liabilities	709,926	704,349
Total liabilities	1,646,003	1,638,917
Commitments and Contingencies (Note 13)
Stockholders’ Deficit:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 103,740 shares in 2017 and 103,341 shares in 2016	10,374	10,334
Additional paid-in capital	1,030,147	1,011,895
Deferred stock units: Outstanding: 225 units in 2017 and 231 units in 2016	5,552	5,514
Retained earnings	609,420	540,401
Accumulated other comprehensive loss	(38,379)	(43,053)
Treasury stock, at cost: 15,807 shares in 2017 and 15,367 shares in 2016	(1,691,204)	(1,633,443)
Total IDEXX Laboratories, Inc. stockholders’ deficit	(74,090)	(108,352)
Noncontrolling interest	178	139
Total stockholders’ deficit	(73,912)	(108,213)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 1,572,091	$ 1,530,704

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Condensed Consolidated Balance Sheets [Abstract]
Accounts receivable, reserves	$ 4,909	$ 4,523
Common stock, par value	$ 0.10	$ 0.10
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	103,740,000	103,341,000
Deferred stock units, outstanding		231,000
Treasury stock, shares	15,807,000	15,367,000

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Product revenue	$ 271,965	$ 249,065
Service revenue	190,056	168,485
Total revenue	462,021	417,550
Cost of Revenue:
Cost of product revenue	103,027	97,631
Cost of service revenue	100,803	92,382
Total cost of revenue	203,830	190,013
Gross profit	258,191	227,537
Expenses:
Sales and marketing	87,244	79,829
General and administrative	52,914	49,295
Research and development	25,790	24,620
Income from operations	92,243	73,793
Interest expense	(8,589)	(8,304)
Interest income	1,083	820
Income before provision for income taxes	84,737	66,309
Provision for income taxes	15,679	20,284
Net income	69,058	46,025
Less: Net income attributable to noncontrolling interest	39	6
Net income attributable to IDEXX Laboratories, Inc. stockholders	$ 69,019	$ 46,019
Earnings per Share:
Basic	$ 0.78	$ 0.51
Diluted	$ 0.77	$ 0.51
Weighted Average Shares Outstanding:
Basic	88,117	89,924
Diluted	89,994	90,838

Condensed Consolidated Stateme5

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 69,058	$ 46,025
Other comprehensive income, net of tax:
Foreign currency translation adjustments	8,014	6,016
Unrealized (loss) gain on net investment hedge	(1,093)	2,224
Unrealized (loss) gain on investments, net of tax (benefit) expense of ($26) in 2017 and $70 in 2016	(39)	205
Unrealized gain (loss) on derivative instruments:
Unrealized loss, net of tax benefit of $912 in 2017 and $1,443 in 2016	(1,534)	(3,266)
Less: reclassification adjustment for gains included in net income, net of tax expense of $401 in 2017 and $170 in 2016	(674)	(429)
Unrealized loss on derivative instruments	(2,208)	(3,695)
Other comprehensive gain, net of tax	4,674	4,750
Comprehensive income	73,732	50,775
Less: comprehensive income attributable to noncontrolling interest	39	6
Comprehensive income attributable to IDEXX Laboratories, Inc.	$ 73,693	$ 50,769

Condensed Consolidated Stateme6

Condensed Consolidated Statements Of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Unrealized (loss) gain on investments, tax (benefit) expense	$ (26)	$ 70
Unrealized loss, net of tax benefit	912	1,443
Reclassification adjustment for gains included in net income, tax expense	$ 401	$ 170

Condensed Consolidated Stateme7

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash Flows from Operating Activities:
Net income	$ 69,058	$ 46,025
Adjustments to reconcile net income to net cash provided (used) by operating activities:
Depreciation and amortization	20,307	18,546
Impairment charge		1,110
Benefit of deferred income taxes	1,941	2,520
Share-based compensation expense	5,655	4,922
Other	860	586
Tax benefit from share-based compensation arrangements (Note 2)		(2,063)
Changes in assets and liabilities:
Accounts receivable	(19,429)	(21,504)
Inventories	(5,369)	1,764
Other assets and liabilities	(38,531)	(23,752)
Accounts payable	(3,687)	(1,801)
Deferred revenue	469	637
Net cash provided by operating activities	31,274	26,990
Cash Flows from Investing Activities:
Purchases of property and equipment	(23,647)	(21,906)
Purchase of marketable securities	(90,492)	(72,079)
Proceeds from the sale and maturities of marketable securities	87,476	70,186
Acquisitions of a business, net of cash acquired	(2,349)
Net cash used by investing activities	(29,012)	(23,799)
Cash Flows from Financing Activities:
Borrowings on revolving credit facilities, net	60,000	49,000
Debt issue costs		(57)
Repurchases of common stock	(63,910)	(53,480)
Proceeds from exercises of stock options and employee stock purchase plans	12,526	5,760
Payment of acquisition-related contingent consideration		(2,084)
Shares withheld for statutory tax withholding on restricted stock (Note 2)	(7,303)	(3,764)
Tax benefit from share-based compensation arrangements (Note 2)		2,063
Net cash provided (used) by financing activities	1,313	(2,562)
Net effect of changes in exchange rates on cash	1,932	3,330
Net increase in cash and cash equivalents	5,507	3,959
Cash and cash equivalents at beginning of period	154,901	128,994
Cash and cash equivalents at end of period	$ 160,408	$ 132,953

Basis Of Presentation And Princ

Basis Of Presentation And Principles Of Consolidation	3 Months Ended
	Mar. 31, 2017
Basis Of Presentation And Principles Of Consolidation [Abstract]
Basis Of Presentation And Principles Of Consolidation	NOTE 1. BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION In order to aid the reader, we have included certain terms and abbreviations used throughout this Quarterly Report on Form 10-Q below:    Term/ Abbreviation Definition   AOCI Accumulated other comprehensive income or loss ASU 2016-09 ASU 2016-09, “ Compensation – Stock Compensation (Topic 781): Improvements to Employee Share-Based Payment Accounting ” CAG Companion Animal Group, a reporting segment that provides to veterinarians diagnostic capabilities and information management solutions that enhance the health and well-being of pets Credit Facility Our $850 million five -year unsecured revolving credit facility under an amended and restated credit agreement that was executed in December 2015 EPS Earnings per share, if not specifically stated, EPS refers to earnings per share on a diluted basis EU European Union FASB Financial Accounting Standards Board LPD Livestock, Poultry and Dairy, a reporting segment that provides diagnostic products and services for livestock and poultry health and to ensure the quality and safety of milk OCI Other comprehensive income or loss OPTI Medical OPTI Medical Systems, Inc., a wholly-owned subsidiary of IDEXX Laboratories Inc., supplies dry slide electrolyte consumables and instruments for the human point-of-care medical diagnostics market, also referred to as OPTI Organic revenue growth A non-GAAP financial measure and represents the percentage change in revenue, as compared to the same period for the prior year, net of the effect of changes in foreign currency exchange rates, acquisitions and divestitures. Organic revenue growth should be considered in addition to, and not as a replacement for or as a superior measure to, revenues reported in accordance with U.S. GAAP, and may not be comparable to similarly titled measures reported by other companies. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. R&D Research and Development SEC U.S. Securities and Exchange Commission Senior Notes Agreement P rivate placement senior notes having an aggregate principal amount of approximately $600 million, referred to as senior notes U.S. GAAP Accounting principles generally accepted in the United States of America Water Water, a reporting segment that provides water quality products around the world  The accompanying condensed consolidated financial statements of IDEXX Laboratories, Inc. and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the requirements of Regulation S-X, Rule 10-01 for financial statements required to be filed as a part of this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to "IDEXX," the "Company," "we," "our" or "us" refer to IDEXX Laboratories, Inc. and its subsidiaries. The accompanying condensed consolidated financial statements include the accounts of IDEXX Laboratories, Inc. and our wholly-owned and majority-owned subsidiaries. We do not have any variable interest entities for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.  The accompanying condensed consolidated financial statements reflect, in the opinion of our management, all adjustments necessary for a fair statement of our financial position and results of operations. All such adjustments are of a recurring nature. The consolidated balance sheet data at December 31, 201 6, was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three months ended March 31 , 201 7, are not necessarily indicative of the results to be expected for the full year or any future period. These condensed consolidated financial statements should be read in conjunction with this Quarterly Report on Form 10- Q for the quarter ended March 31 , 201 7, and our Annual Report on Form 10-K for the year ended December 31, 201 6, (the “2016 Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”).  For the three months ended March 31, 2017 , changes in stockholders’ equity included (i) changes in other comprehensive income reflected in the condensed consolidated statements of comprehensive incom e; (ii) changes in common stock and additional paid-in capital reflected in the condensed consolidated statements of cash flows (including share-based compensation expense, proceeds from exercise of stock option s and employee stock purchase plans and repurchases of common stock); (iii) changes in noncontrolling interest; and (iv) changes in net income. 

Accounting Policies

Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Accounting Policies	N OTE 2. ACCOUNTING POLICIES  Significant Accounting Policies  The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2017 are consistent with those discussed in Note 2 to the consolidated financial statements in our 2016 Annual Report, except as noted below.  New Accounting Pronouncements Adopted  Effective January 1, 2017, we adopted the Financial Accounting Standards Board (“FASB”) standard update ASU 2016-09, “ Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ” (“ASU 2016-09”) which simplifies several aspects of the accounting for share-based payment transactions, including income tax consequences, recognition of stock compensation award forfeitures, classification of awards as either equity or liabilities, the calculation of diluted shares outstanding and classification on the statement of cash flows.  The following table summarizes the most significant impacts of the new accounting guidance for the th ree months ended March 31, 2017 and 2016, if applicable :     Description of Change: Impact of Change for the Three Months Ended March 31, 2017 and 2016 if applicable: Adoption Method:  Tax benefits related to share-based payments at settlement are recorded through the income statement instead of equity Decrease in income tax expense by approximately $11.2 million for the three months ended March 31, 2017 Prospective (elected)   Calculation of diluted shares outstanding under the treasury method will no longer assume that tax benefits related to share-based payments are used to repurchase common stock Increase in the weighted average diluted shares outstanding by approximately 450,000 shares for the three months ended March 31, 2017 Prospective (required)   An election can be made to reduce share-based compensation expense for forfeitures as they occur instead of estimating forfeitures that are expected to occur No change to share-based compensation expense, as we have elected to continue to estimate forfeitures that are expected to occur N/A   Tax benefits related to share-based payments at settlement are classified as operating cash flows instead of financing cash flows Increase in cash flow from operating activities and decrease in cash flow from financing activities by approximately $11.2 million for the three months ended March 31, 2017 Prospective (elected)   Cash payments to tax authorities for shares withheld to meet employee tax withholding requirements on restricted stock units are classified as financing cash flow instead of operating cash flow Increase in cash flow from operating activities and decrease in cash flow from financing activities for the three months ended March 31, 2017 and 2016 by approximately $7.3 million and $3.8 million, respectively Retrospective (required)  New Accounting Pronouncements Not Yet Adopted  In May 2014, the FASB issued Accounting Standard Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) , which will replace most of the existing revenue recognition guidance within U.S. GAAP. The FASB has also issued several updates to ASU 2014-09. The core principle of ASU 2014-09 is that an entity should recognize revenue for the transfer of goods or services to customers in an amount that it expects to be entitled to receive for those goods or services. In doing so, companies will be required to make certain judgments and estimates, including identifying contract performance obligations, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price among separate performance obligations. Additionally, disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments reached in the application of the guidance and assets recognized from the costs to obtain or fulfill a contr act will be required . In July 2015, the FASB approved a one-year deferral of the effective date to all annual and interim periods beginning after December 15, 2017. The new guidance permits two methods of adoption: a full retrospective method to each prior reporting period presented or a modified retrospective approach with the cumulative effect of initially applying the guidance recognized at the date of initial application. We are continuing to evaluate the impact of this new standard . While ASU 2014-09 will not impact the overall economics of our products and services sold under customer incentive programs, we do expect the new standard will require us to delay revenue recognition related to certain of our customer ince ntive programs and to accelerate revenue recognition for certain other customer incentive programs. The volume and mix of future customer incentive programs will affect our assessment of the overall net impact of the new standard on our results and will also influence our choice of adoption method. We plan to determine our method of adoption and provide an estimate of any impacts by October 2017, in connection with our financial reporting for the quarter ending September 30, 2017.  In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , to increase transparency and comparability among organizations’ leasing arrangements. The principal difference from previous guidance is that effective upon adoption, the lease assets and lease liabilities arising from operating leases will be recognized in the balance sheet. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. In transition, we are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, including the option to utilize a number of practical expedients. We are in process of evaluating our lessee and lessor arrangements to determine the impact of this amendment on the consolidated financial statements. This evaluation includes an extensive review of revenue through leasing arrangements as well as lease expenses, which are primarily through operating lease arrangements for most of our facilities.  In February 2017, the FASB issued ASU 2017-05, Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets. The ASU clarifies the scope and accounting of a financial asset that meets the definition of an “in-substance nonfinancial asset” and defines the term, “in-substance nonfinancial asset.” The ASU also adds guidance for parti al sales of nonfinancial assets . The new guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those years. Early adoption is permitted for interim or annual reporting periods beginning after December 15, 2016. The guidance may be applied retrospectively for all periods presented or retrospectively with a cumulative-effect adjustment at the date of adoption. The Company is currently evaluating the effects of ASU 2017-05 on its consolidated financial statements .

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2017
Share-Based Compensation [Abstract]
Share-Based Compensation	 NOTE 3 . SHARE-BASED COMPENSATION The fair value of options, restricted stock units, deferred stock units and employee stock purchase rights awarded during the three months ended March 31, 2017, totaled $27.9 million as compared to $24.0 million for the three months ended March 31, 2016 . T he total unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensatio n awards outstanding at March 31, 2017, was $58.0 million, which will be recognized over a weighted average period of approximately 2 .3 years . We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards.  The weighted averages of the valuation assumptions used to determine the fair value of each option award on the date of grant and the weighted average estimated fair values were as follows:   For the Three Months Ended  March 31,  2017 2016   Share price at grant $ 141.60 $ 67.85  Expected stock price volatility 26 % 25 %  Expected term, in years 5.8 5.7  Risk-free interest rate 2.0 % 1.2 %  Weighted average fair value of options granted $ 40.51 $ 17.54 

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2017
Marketable Securities [Abstract]
Marketable Securities	 Note 4 . marketable securities  The amortized cost and fair value of marketable securities were as follows ( in thousands ):    As of March 31, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 120,898 $ 76 $ (81) $ 120,893  Certificates of deposit 43,198 - - 43,198  Asset backed securities 37,610 6 (16) 37,600  Commercial paper 17,013 - - 17,013  U.S. government bonds 16,644 1 (15) 16,630  Agency bonds 4,600 - (1) 4,599  Total marketable securities $ 239,963 $ 83 $ (113) $ 239,933   As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 130,833 $ 40 $ (102) $ 130,771  Certificates of deposit 40,400 - - 40,400  Asset backed securities 27,290 25 - 27,315  Commercial paper 20,228 - - 20,228  U.S. government bonds 12,244 1 (14) 12,231  Agency bonds 4,600 4 - 4,604  Municipal bonds 1,400 - - 1,400  Total marketable securities $ 236,995 $ 70 $ (116) $ 236,949  As of March 31, 2017, unrealized losses on marketable securities that have been in a continuous loss position for more than twelve months were not material. Our portfolio of marketable securities had an average AA- credit rating as of March 31, 2017. There were no marketable securities that we consider to be other-than-temporarily impaired as of March 31, 2017.  Remaining effective maturities of marketable securities were as follows ( in thousands ):     As of March 31, 2017 Amortized Cost Fair Value   Due in one year or less $ 144,581 $ 144,547  Due after one year through three years 95,382 95,386  $ 239,963 $ 239,933  Our investment strategy is to buy short-duration marketable securities with a high credit rating. Some of our marketable securities have call features that can effectively shorten the lifespan from the contractual maturity date. We use the effective maturity date to measure the duration of the marketable securities.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2017
Inventories [Abstract]
Inventories	 Note 5 . Inventories Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges. The components of inventories were as follows (in thousands) :    March 31, December 31,  2017 2016   Raw materials $ 28,232 $ 27,561  Work-in-process 18,804 14,998  Finished goods 125,147 115,475  Inventories $ 172,183 $ 158,034 

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets, Net [Abstract]
Goodwill And Intangible Assets, Net	Note 6. Goodwill and Intangible Assets, NET We believe that acquisitions of business and other assets enhances our existing businesses by either expanding ou r geographic range and customer base or expanding our existing product lines. During the three months ended March 31, 2017, we acquired one reference laboratory in Austria for approximately $1.6 million, with a majority of the acquisition price valued as an intangible asset.  During 2016, management reviewed our OPTI Medical product offerings. As a result of this review, we discontinued our product development activities in human point-of-care medical diagnostics. As a result of this change in strategy, we assessed the realizability of the related tangible and intangible assets and determined the expected future cash flows were less than the carrying value of the asset group and recorded a non-cash intangible asset impairment of $ 2 . 2 million within our condensed consolidated statement of operations within general and administration expense during 2016, of which, $1.1 million of expense was recorded during the first quarter of 2016 . 

Other Current and Long-Term Ass

Other Current and Long-Term Assets	3 Months Ended
	Mar. 31, 2017
Other Current and Long-Term Assets [Abstract]
Other Current and Long-Term Assets	NOTE 7. Other current and long-term ASSETS  Other current assets consisted of the following (in thousands) :    March 31, December 31,  2017 2016   Prepaid expenses $ 25,330 $ 25,746  Taxes receivable 20,217 27,672  Customer acquisition costs, net 19,364 18,085  Other assets 15,800 19,703  Other current assets $ 80,711 $ 91,206  Other long-term assets consisted of the following (in thousands) :    March 31, December 31,  2017 2016   Investment in long-term product supply arrangements $ 10,170 $ 10,978  Customer acquisition costs, net 54,602 50,309  Other assets 35,344 36,321  Deferred income taxes 5,867 5,707  Other long-term assets $ 105,983 $ 103,315 

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities [Abstract]
Accrued Liabilities	Note 8 . Accrued liabilities Accrued liabilities consisted of the following (in thousands) :    March 31, December 31,  2017 2016   Accrued expenses $ 55,545 $ 71,984  Accrued employee compensation and related expenses 49,249 91,113  Accrued taxes 21,272 23,973  Accrued customer programs 48,697 49,061  Accrued liabilities $ 174,763 $ 236,131 

Repurchases Of Common Stock

Repurchases Of Common Stock	3 Months Ended
	Mar. 31, 2017
Repurchases Of Common Stock [Abstract]
Repurchases Of Common Stock	Note 9 . Repurchases of common STOCK  We primarily acquire shares by repurchases in the open market. However, we also acquire shares tha t are surrendered by employees in payment for the minimum required statutory withholding taxes due on the vesting of restricted stock units and the settlement of deferred stock units, otherwise referred to herein as employee surrenders.  We issue shares of treasury stock upon the vesting of certain restricted stock units and upon the exercise of certain stock options. The number of shares of treasury st ock issued during the three months ended March 31, 2017 and 201 6 was not material.  The following is a summary of our open market common stock repurchases , reported on a trade date basis, and shares acquired through employee surrender for the three months ended March 31 , 201 7 and 201 6 (in thousands, except per share amounts) :    For the Three Months Ended  March 31,  2017 2016   Shares repurchased in the open market 390 708  Shares acquired through employee surrender for statutory tax withholding 52 52  Total shares repurchased 442 760   Cost of shares repurchased in the open market $ 50,744 $ 49,715  Cost of shares for employee surrenders 7,303 3,529  Total cost of shares $ 58,047 $ 53,244   Average cost per share - open market repurchase $ 130.12 $ 70.21  Average cost per share - employee surrenders $ 141.09 $ 67.96  Average cost per share - total $ 131.41 $ 70.06 

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Taxes [Abstract]
Income Taxes	 Note 10 . Income Taxes Our effective income tax rate was 18.5 percent for the three months ended March 31, 2017, as compared to 30.6 percent for the three months ended March 31, 2016. The decrease in our effective tax rate for the three months ended March 31, 2017, as compared to the same period of the prior year, was primarily related to the adoption of FASB issued amendments related to share-based compensation discussed further in “Note 2. Accounting Policies”. The change in accounting guidance reduced our effective income tax rate for the three months ended March 31, 2017, by approximately 13 percentage points.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2017
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income	Note 1 1 . ACCUMULATED OTHER Comprehensive Income The changes in accumulated other comprehensive income (“ AOCI ”), net of tax, for the three months ended March 31 , 201 7 consisted of the following (in thousands) :   For the Three Months Ended March 31, 2017 Unrealized Gain (Loss) on Investments, Net of Tax Unrealized Gain (Loss) on Derivative Instruments, Net of Tax Unrealized Gain (Loss) on Net Investment Hedge, Net of Tax Cumulative Translation Adjustment Total   Balance as of December 31, 2016 $ 20 $ 4,916 $ 4,036 $ (52,025) $ (43,053)  Other comprehensive (loss) income before reclassifications (39) (1,534) (1,093) 8,014 5,348  Gains reclassified from accumulated other comprehensive income - (674) - - (674)  Balance as of March 31, 2017 $ (19) $ 2,708 $ 2,943 $ (44,011) $ (38,379)          The following is a summary of reclassifications out of AOCI for the three months ended March 31 , 201 7 and 201 6 (in thousands) :     Details about AOCI Components Affected Line Item in the Statement of Operations Amounts Reclassified from AOCI For the Three Months Ended March 31,  2017 2016  Gains (losses) on derivative instruments classified as cash flow hedges included in net income:  Foreign currency exchange contracts Cost of revenue $ 1,075 $ 809  Interest rate swaps Interest expense - (210)  Total gains before tax 1,075 599  Tax expense 401 170  Gains, net of tax $ 674 $ 429  

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	 Note 1 2 . Earnings per Share Basic earnings per share is computed by dividing net income attributable to our stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options, the total unrecognized compensation expense for unvested share-based compensation awards and, prior to the adoption of new accounting guidance related to share-based compensation on January 1, 2017, the tax benefits resulting from share-based compensation tax deductions in excess of the related expense recognized for financial reporting purposes, would be used to purchase our common stock at the average market price during the period. For further discussion regarding the impact of the new accounting guidance related to share-based compensation, see Note 2 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent. See Note 4 to the consolidated financial statements in our 201 6 Annual Report for additional information regarding deferred stock units.  The following is a reconciliation of weighted average shares outstanding for basic and diluted earnings per share for the three months ended March 31 , 201 7 and 201 6 (in thousands) :   For the Three Months Ended  March 31,  2017 2016   Shares outstanding for basic earnings per share 88,117 89,924   Shares outstanding for diluted earnings per share:  Shares outstanding for basic earnings per share 88,117 89,924  Dilutive effect of share-based payment awards 1,877 914  89,994 90,838    C ertain options to acquire shares and restricted stock units have been excluded from the calculation of shares outstanding for diluted earnings per share because they were anti-dilutive. The following table presents information concerning those anti-dilutive options and restricted stock units for the three months ended March 3 1 , 201 7 and 2016 (in thousands ):   For the Three Months Ended  March 31,  2017 2016   Weighted average number of shares underlying anti-dilutive options 182 1,044   Weighted average number of shares underlying anti-dilutive restricted stock units 47 - 

Commitments, Contingencies And

Commitments, Contingencies And Guarantees	3 Months Ended
	Mar. 31, 2017
Commitments, Contingencies And Guarantees [Abstract]
Commitments, Contingencies And Guarantees	Note 13 . Commitments, Contingencies and Guarantees Significant commitments, contingencies and guarantees at March 3 1 , 201 7 are consistent with those discussed in Note 1 4 to the consolidated financial statements in our 201 6 Annual Report .

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segment Reporting	Note 1 4 . Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”) , or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. Our reportable segments include diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality produc ts (“Water”) and diagnostic product s and services for livestock and poultry health and to ensure the quality and safety of milk and food, which we refer to as Livestock, Poultry and Dairy (“LPD”). Our Other operating segment combines and presents products for the human point-of-care medical diagnostics market with our pharmaceutical product line and our out-licensing arrangements because they do not meet the quantitative or qualitative thresholds for reportable segments.  Certain costs are not allocated to our operating segments and are instead reported under the caption “Unallocated Amounts”. These costs include costs that do not align with one of our existing operating segments or are cost prohibitive to allocate, which primarily consist of our R&D function, regional or country expenses, certain foreign currency revaluation gains and losses on monetary balances in currencies other than our subsidiaries’ functional currency and unusual items. Corporate support function costs (such as information technology, facilities, human resources, finance and legal), health benefits and incentive compensation are charged to our business segments at pre-determined budgeted amounts or rates. Differences from these pre-determined budgeted amounts or rates are captured within Unallocated Amounts. The following is a summary of segment p erformance for the three months ended March 3 1 , 201 7 and 201 6 (in thousands) :       For the Three Months Ended March 31,  CAG Water LPD Other Unallocated Amounts Consolidated Total  2017  Revenue $ 403,227 $ 25,077 $ 29,317 $ 4,400 $ - $ 462,021   Income (loss) from operations $ 79,855 $ 10,263 $ 3,802 $ 393 $ (2,070) $ 92,243  Interest expense, net (7,506)  Income before provision for income taxes 84,737  Provision for income taxes 15,679  Net income 69,058  Less: Net income attributable to noncontrolling interest 39  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 69,019   2016  Revenue $ 357,639 $ 23,552 $ 30,856 $ 5,503 $ - $ 417,550   Income (loss) from operations $ 61,378 $ 9,679 $ 4,570 $ (837) $ (997) $ 73,793  Interest expense, net (7,484)  Income before provision for income taxes 66,309  Provision for income taxes 20,284  Net income 46,025  Less: Net income attributable to noncontrolling interest 6  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 46,019   The following is a summary of revenue by product and servic e category for the three months ended March 3 1 , 201 7 and 201 6 ( in thousands ):   For the Three Months Ended  March 31,  2017 2016  CAG segment revenue:  CAG Diagnostics recurring revenue: $ 346,680 $ 305,841  IDEXX VetLab consumables 123,553 107,969  Rapid assay products 47,895 43,086  Reference laboratory diagnostic and consulting services 159,069 140,708  CAG Diagnostics service and accessories 16,163 14,078  CAG Diagnostics capital - instruments 26,183 22,643  Veterinary software, services and diagnostic imaging systems 30,364 29,155  CAG segment revenue 403,227 357,639   Water segment revenue 25,077 23,552  LPD segment revenue 29,317 30,856  Other segment revenue 4,400 5,503  Total revenue $ 462,021 $ 417,550 

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Measurements [Abstract]
Fair Value Measurements	 Note 15 . FAIR VALUE MEASUREMENTS U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.  The Company has certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a nonrecurring basis and certain financial assets and liabilities that are not measured at fair value in our condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows : Level 1 Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the three months ended March 31, 2017.  Our marketable debt securities are initially valued at the transaction price and are subsequently remeasured to fair value as of the balance sheet date utilizing third- party pricing services. The pricing services utilize industry standard valuation models, i ncluding both income and market- based approaches and observable market inputs to determine value. Observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers and other industry and economic events. We validate t he prices provided by our third- party pricing services by obtaining independent market values from other pricing sources and analyzing pricing data in certain instances.  Our foreign currency exchange contracts and interest rate swap agreements are measured at fair value on a recurring basis in our accompanying condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk.  W e measure the fair value of our interest rate swaps classified as derivative instruments using an income approach, utilizing a discounted cash flow analysis based on the terms of the contract and the interest rate curve adjusted for counterparty risk. As of March 31, 2017, and December 31, 2016, we had no outstanding interest rate swap agreements. The amount s outstanding under our unsecured revolving credit facility (“Credit Facility” or “line of credit” ) and senior notes (“long-term debt”) are measured at carrying value in our condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and l ong-term debt are valued using L evel 2 inputs. The estimated fair value of our Credit Facility approximates its carrying value. The estimated fair value and carrying value of our long-term debt were $611.0 million and $ 595.4 million, respectively, as of March 31, 2017, and $609.5 million and $593.7 million, respectively, as of December 31, 2016. The following tables set forth our assets and liabilities that were measured at fair val ue on a recurring basis at March 31 , 201 7 and at December 31, 201 6 by level within the fair value hierarchy (in thousands) :    Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of March 31, 2017 (Level 1) (Level 2) (Level 3) March 31, 2017   Assets  Money market funds (1) $ 26,523 $ - $ - $ 26,523  Certificates of deposit (1) - 2,001 - 2,001  Commercial paper (1) - 2,998 - 2,998   Marketable Securities  Corporate bonds - 120,893 - 120,893  Certificates of deposit - 43,198 - 43,198  Asset backed securities - 37,600 - 37,600  Commercial paper - 17,013 - 17,013  U.S. government bonds - 16,630 - 16,630  Agency bonds - 4,599 - 4,599  Total marketable securities - 239,933 - 239,933   Equity mutual funds (2) 2,196 - - 2,196  Foreign currency exchange contracts (3) - 5,445 - 5,445  Liabilities  Foreign currency exchange contracts (3) - 1,344 - 1,344  Deferred compensation (4) 2,196 - - 2,196     Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of December 31, 2016 (Level 1) (Level 2) (Level 3) December 31, 2016   Assets  Money market funds (1) $ 34,208 $ - $ - $ 34,208  Certificates of deposit (1) - 1,500 - 1,500  Commercial paper (1) - 898 - 898   Marketable Securities  Corporate bonds - 130,771 - 130,771  Certificates of deposit - 40,400 - 40,400  Asset backed securities - 27,315 - 27,315  Commercial paper - 20,228 - 20,228  U.S. government bonds - 12,231 - 12,231  Agency bonds - 4,604 - 4,604  Municipal bonds - 1,400 - 1,400  Total marketable securities - 236,949 - 236,949   Equity mutual funds (2) 2,182 - - 2,182  Foreign currency exchange contracts (3) - 8,926 - 8,926  Liabilities  Foreign currency exchange contracts (3) - 1,081 - 1,081  Deferred compensation (4) 2,182 - - 2,182 _____________ (1) Money market funds, certificates of deposit and commercial paper with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of March 3 1 , 201 7 and December 31, 201 6 consisted of demand deposits. Commercial paper and certificates of deposit with an original maturity of over ninety days are included within marketable securities. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets. See footnote (4) below for a discussion of the related deferred compensation liability. (3) Foreign currency exchange contracts are included within other current assets; other long-term assets; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date. (4) A deferred compensation plan assumed as part of a previous business combination is included within accrued liabilities and other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in footnote (2) above. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate carrying value due to their short maturity.

Hedging Instruments

Hedging Instruments	3 Months Ended
	Mar. 31, 2017
Hedging Instruments [Abstract]
Hedging Instruments	 Note 1 6 . HEDGING Instruments Disclosure within this note is presented to provide transparency about how and why we use derivative and non-derivative instruments (collectively “hedging instruments”) , how the instruments and related hedged items are accounted for, and how the instruments and related hedged items affect our financial position, results of operations and cash flows. We are exposed to certain risks related to our ongoing business operations. The primary risks that we manage by using hedging instruments are foreign currency exchange risk and interest rate risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures , including net investments in certain foreign subsidiaries. We may also enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility. The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in the euro, British pound, Japanese yen, Canadian dollar, Australian dollar and Swiss franc. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign curre ncy exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in t ransactions involving hedging instruments for purposes other than risk management. Our accounting policies for these contracts are based on the designation of such instruments as hedging transactions.  We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. I nstruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cas h flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, c hanges in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earn ings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See Note 11 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further information regarding the effect of hedging instruments on the condensed consolidated statements of operations for the three months ended March 3 1 , 201 7 and 201 6 .  We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts and interest rate swaps are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged. Cash Flow Hedges We have designated our foreign currency exchange contracts and variable-to-fixed interest rate swaps as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange and interest rates. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment. We did not de-designate any instruments from hedge accounting treatment during the three months ended March 31 , 201 7 or 201 6 . Gains or losses related to hedge ineffectiveness recognized in earnings during the three months ended March 3 1 , 201 7 and 201 6 were not material . At March 3 1 , 201 7 , the estimated amount of net gains , net of income tax expense, which are expected to be reclassified out of AOCI and into earnings within the next 12 months, is $2.5 million if exchange rates do not fluctuate from the levels at March 3 1 , 201 7 . W e hedge approximately 85 percent of the estimated exposure from intercompany product purchases and sales denominated in the euro, British pound, Canadian dollar, Japanese yen, Australian dollar and Swiss franc. We have additional unhedged foreign currency exposures related to foreign services and emerging markets where it is not practical to hedge. We primarily utilize foreign currency exchange contracts with durations of less than 24 months. Quarterly, we enter into contracts to hedge incremental portions of anticipated foreign currency transactions for the current and following year. As a result, our risk with respect to foreign currency exchange rate fluctuations and the notional value of foreign currency exchange contracts may vary throughout the year. The U.S. dollar is the currency purchased or sold in all of our foreign currency exchange contracts . The notional amount of foreign currency exchange contracts to hedge forecasted intercompany inventory purchases and sales totaled $203.5 million and $175.9 million at March 31, 201 7 and December 31, 2016, respectively. We previously entered into forward fixed interest rate swap agreements to manage the economic effect of variable interest obligations on amounts borrowed under the terms of our Credit Facility. Beginning on March 30, 2012, the variable interest rate associated with $40 million of borrowings outstanding under the Credit Facility was effectively fixed at 1.36 percent plus the range of applicable interest rate fixed credit spreads (“Credit Spread”) through June 30, 2016 . Beginning on March 28, 2013, the variable interest rate associated with an additional $40 million of borrowings outstanding under the Credit Facility was effectively fixed at 1.64 percent plus the Credit Spread through June 30, 2016 . From July 1, 2016, to March 31, 2017, we had no outstanding interest rate swap agreements .  Net Investment Hedge  In June 2015, we issued and sold through a private placement an aggregate principal amount of €88.9 million in euro-denominated 1.785 percent Series C Senior Notes due June 18, 2025. We have designated these euro-denominated notes as a hedge of our euro net investment in certain foreign subsidiaries to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates in the euro relative to the U.S. dollar. As a result of this designation, gains and losses from the change in translated U.S. dollar value of these euro-denominated notes are recorded in AOCI rather than to earnings . We recorded a $1.1 million loss , net of income tax, within AOCI as a result of this net investment hedge for the three months end ed March 31, 2017 . The related cumulative unrealized gain recorded at March 3 1 , 201 7 will not be reclassified in earnings until the complete or substantially complete liquidation of the net investment in the hedged foreign operations or a portion of the hedge no longer qualifies for hedge accounting treatment. See Note 11 to the consolidated financial statements included in our 201 6 Annual Report for further information regarding the issuance of these euro-denominated notes.  Fair Values of Hedging Instruments Designated as Hedges in Consolidated Balance Sheets  The fair values of hedging instruments and their respective classification on the condensed consolidated balance sheets and amounts subject to offset under master netting arrangements consisted of the following (in thousands) :   Hedging Assets  March 31, December 31,  2017 2016   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Other current assets $ 4,937 $ 8,926  Foreign currency exchange contracts Other long-term assets 508 -  Total derivative instruments presented as cash flow hedges on the balance sheet 5,445 8,926  Gross amounts subject to master netting arrangements not offset on the balance sheet 1,082 679  Net amount $ 4,363 $ 8,247     Hedging Liabilities  March 31, December 31,  2017 2016   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Accrued liabilities $ 1,174 $ 1,081  Foreign currency exchange contracts Other long-term liabilities 170 -  Total derivative instruments presented as cash flow hedges on the balance sheet 1,344 1,081  Foreign currency borrowings designated as net investment hedge on the balance sheet Long-term debt 95,406 93,664  Total hedging instruments presented on the balance sheet 96,750 94,745  Gross amounts subject to master netting arrangements not offset on the balance sheet 1,082 679  Net amount $ 95,668 $ 94,066  The effect of derivative instruments designated as cash flow hedges on the condensed consolidated balance sheets consisted of the following (in thousands) :    Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion)  For the Three Months Ended  March 31,  Derivative instruments 2017 2016   Cash flow hedging derivatives:  Foreign currency exchange contracts, net of tax $ (2,208) $ (3,806)  Interest rate swaps, net of tax - 111  Total cash flow hedges $ (2,208) $ (3,695) 

Accounting Policies (Policy)

Accounting Policies (Policy)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
New Accounting Pronouncements Adopted	 New Accounting Pronouncements Adopted  Effective January 1, 2017, we adopted the Financial Accounting Standards Board (“FASB”) standard update ASU 2016-09, “ Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ” (“ASU 2016-09”) which simplifies several aspects of the accounting for share-based payment transactions, including income tax consequences, recognition of stock compensation award forfeitures, classification of awards as either equity or liabilities, the calculation of diluted shares outstanding and classification on the statement of cash flows.  The following table summarizes the most significant impacts of the new accounting guidance for the th ree months ended March 31, 2017 and 2016, if applicable :     Description of Change: Impact of Change for the Three Months Ended March 31, 2017 and 2016 if applicable: Adoption Method:  Tax benefits related to share-based payments at settlement are recorded through the income statement instead of equity Decrease in income tax expense by approximately $11.2 million for the three months ended March 31, 2017 Prospective (elected)   Calculation of diluted shares outstanding under the treasury method will no longer assume that tax benefits related to share-based payments are used to repurchase common stock Increase in the weighted average diluted shares outstanding by approximately 450,000 shares for the three months ended March 31, 2017 Prospective (required)   An election can be made to reduce share-based compensation expense for forfeitures as they occur instead of estimating forfeitures that are expected to occur No change to share-based compensation expense, as we have elected to continue to estimate forfeitures that are expected to occur N/A   Tax benefits related to share-based payments at settlement are classified as operating cash flows instead of financing cash flows Increase in cash flow from operating activities and decrease in cash flow from financing activities by approximately $11.2 million for the three months ended March 31, 2017 Prospective (elected)   Cash payments to tax authorities for shares withheld to meet employee tax withholding requirements on restricted stock units are classified as financing cash flow instead of operating cash flow Increase in cash flow from operating activities and decrease in cash flow from financing activities for the three months ended March 31, 2017 and 2016 by approximately $7.3 million and $3.8 million, respectively Retrospective (required) 
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted  In May 2014, the FASB issued Accounting Standard Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) , which will replace most of the existing revenue recognition guidance within U.S. GAAP. The FASB has also issued several updates to ASU 2014-09. The core principle of ASU 2014-09 is that an entity should recognize revenue for the transfer of goods or services to customers in an amount that it expects to be entitled to receive for those goods or services. In doing so, companies will be required to make certain judgments and estimates, including identifying contract performance obligations, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price among separate performance obligations. Additionally, disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments reached in the application of the guidance and assets recognized from the costs to obtain or fulfill a contr act will be required . In July 2015, the FASB approved a one-year deferral of the effective date to all annual and interim periods beginning after December 15, 2017. The new guidance permits two methods of adoption: a full retrospective method to each prior reporting period presented or a modified retrospective approach with the cumulative effect of initially applying the guidance recognized at the date of initial application. We are continuing to evaluate the impact of this new standard . While ASU 2014-09 will not impact the overall economics of our products and services sold under customer incentive programs, we do expect the new standard will require us to delay revenue recognition related to certain of our customer ince ntive programs and to accelerate revenue recognition for certain other customer incentive programs. The volume and mix of future customer incentive programs will affect our assessment of the overall net impact of the new standard on our results and will also influence our choice of adoption method. We plan to determine our method of adoption and provide an estimate of any impacts by October 2017, in connection with our financial reporting for the quarter ending September 30, 2017.  In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , to increase transparency and comparability among organizations’ leasing arrangements. The principal difference from previous guidance is that effective upon adoption, the lease assets and lease liabilities arising from operating leases will be recognized in the balance sheet. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. In transition, we are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, including the option to utilize a number of practical expedients. We are in process of evaluating our lessee and lessor arrangements to determine the impact of this amendment on the consolidated financial statements. This evaluation includes an extensive review of revenue through leasing arrangements as well as lease expenses, which are primarily through operating lease arrangements for most of our facilities.  In February 2017, the FASB issued ASU 2017-05, Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets. The ASU clarifies the scope and accounting of a financial asset that meets the definition of an “in-substance nonfinancial asset” and defines the term, “in-substance nonfinancial asset.” The ASU also adds guidance for parti al sales of nonfinancial assets . The new guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those years. Early adoption is permitted for interim or annual reporting periods beginning after December 15, 2016. The guidance may be applied retrospectively for all periods presented or retrospectively with a cumulative-effect adjustment at the date of adoption. The Company is currently evaluating the effects of ASU 2017-05 on its consolidated financial statements

Share-Based Compensation (Polic

Share-Based Compensation (Policy)	3 Months Ended
	Mar. 31, 2017
Share-Based Compensation [Abstract]
Share-Based Compensation Policy	We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards.

Inventories (Policy)

Inventories (Policy)	3 Months Ended
	Mar. 31, 2017
Inventories [Abstract]
Inventories Policy	Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges.

Earnings Per Share (Policy)

Earnings Per Share (Policy)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share Policy	Basic earnings per share is computed by dividing net income attributable to our stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options, the total unrecognized compensation expense for unvested share-based compensation awards and, prior to the adoption of new accounting guidance related to share-based compensation on January 1, 2017, the tax benefits resulting from share-based compensation tax deductions in excess of the related expense recognized for financial reporting purposes, would be used to purchase our common stock at the average market price during the period. For further discussion regarding the impact of the new accounting guidance related to share-based compensation, see Note 2 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent.

Fair Value Measurements (Policy

Fair Value Measurements (Policy)	3 Months Ended
	Mar. 31, 2017
Fair Value Measurements [Abstract]
Fair Value Measurements Policy	U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.  The Company has certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a nonrecurring basis and certain financial assets and liabilities that are not measured at fair value in our condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows : Level 1 Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the three months ended March 31, 2017.  Our marketable debt securities are initially valued at the transaction price and are subsequently remeasured to fair value as of the balance sheet date utilizing third- party pricing services. The pricing services utilize industry standard valuation models, i ncluding both income and market- based approaches and observable market inputs to determine value. Observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers and other industry and economic events. We validate t he prices provided by our third- party pricing services by obtaining independent market values from other pricing sources and analyzing pricing data in certain instances.  Our foreign currency exchange contracts and interest rate swap agreements are measured at fair value on a recurring basis in our accompanying condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk.  W e measure the fair value of our interest rate swaps classified as derivative instruments using an income approach, utilizing a discounted cash flow analysis based on the terms of the contract and the interest rate curve adjusted for counterparty risk. As of March 31, 2017, and December 31, 2016, we had no outstanding interest rate swap agreements. The amount s outstanding under our unsecured revolving credit facility (“Credit Facility” or “line of credit” ) and senior notes (“long-term debt”) are measured at carrying value in our condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and l ong-term debt are valued using L evel 2 inputs.

Hedging Instuments (Policy)

Hedging Instuments (Policy)	3 Months Ended
	Mar. 31, 2017
Hedging Instruments [Abstract]
Derivatives Policy	We are exposed to certain risks related to our ongoing business operations. The primary risks that we manage by using hedging instruments are foreign currency exchange risk and interest rate risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures , including net investments in certain foreign subsidiaries. We may also enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility. The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in the euro, British pound, Japanese yen, Canadian dollar, Australian dollar and Swiss franc. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign curre ncy exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in t ransactions involving hedging instruments for purposes other than risk management. Our accounting policies for these contracts are based on the designation of such instruments as hedging transactions.  We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. I nstruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cas h flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, c hanges in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earn ings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See Note 11 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further information regarding the effect of hedging instruments on the condensed consolidated statements of operations for the three months ended March 3 1 , 201 7 and 201 6 .  We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts and interest rate swaps are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged. Cash Flow Hedges We have designated our foreign currency exchange contracts and variable-to-fixed interest rate swaps as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange and interest rates. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment.

Accounting Policies (Tables)

Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Summary Of The Most Significant Impacts Of The New Accounting Guidance	  Description of Change: Impact of Change for the Three Months Ended March 31, 2017 and 2016 if applicable: Adoption Method:  Tax benefits related to share-based payments at settlement are recorded through the income statement instead of equity Decrease in income tax expense by approximately $11.2 million for the three months ended March 31, 2017 Prospective (elected)   Calculation of diluted shares outstanding under the treasury method will no longer assume that tax benefits related to share-based payments are used to repurchase common stock Increase in the weighted average diluted shares outstanding by approximately 450,000 shares for the three months ended March 31, 2017 Prospective (required)   An election can be made to reduce share-based compensation expense for forfeitures as they occur instead of estimating forfeitures that are expected to occur No change to share-based compensation expense, as we have elected to continue to estimate forfeitures that are expected to occur N/A   Tax benefits related to share-based payments at settlement are classified as operating cash flows instead of financing cash flows Increase in cash flow from operating activities and decrease in cash flow from financing activities by approximately $11.2 million for the three months ended March 31, 2017 Prospective (elected)   Cash payments to tax authorities for shares withheld to meet employee tax withholding requirements on restricted stock units are classified as financing cash flow instead of operating cash flow Increase in cash flow from operating activities and decrease in cash flow from financing activities for the three months ended March 31, 2017 and 2016 by approximately $7.3 million and $3.8 million, respectively Retrospective (required) 

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Share-Based Compensation [Abstract]
Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards	  For the Three Months Ended  March 31,  2017 2016   Share price at grant $ 141.60 $ 67.85  Expected stock price volatility 26 % 25 %  Expected term, in years 5.8 5.7  Risk-free interest rate 2.0 % 1.2 %  Weighted average fair value of options granted $ 40.51 $ 17.54 

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2017
Marketable Securities [Abstract]
Amortized Cost And Fair Value Of Marketable Securities	  As of March 31, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 120,898 $ 76 $ (81) $ 120,893  Certificates of deposit 43,198 - - 43,198  Asset backed securities 37,610 6 (16) 37,600  Commercial paper 17,013 - - 17,013  U.S. government bonds 16,644 1 (15) 16,630  Agency bonds 4,600 - (1) 4,599  Total marketable securities $ 239,963 $ 83 $ (113) $ 239,933   As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 130,833 $ 40 $ (102) $ 130,771  Certificates of deposit 40,400 - - 40,400  Asset backed securities 27,290 25 - 27,315  Commercial paper 20,228 - - 20,228  U.S. government bonds 12,244 1 (14) 12,231  Agency bonds 4,600 4 - 4,604  Municipal bonds 1,400 - - 1,400  Total marketable securities $ 236,995 $ 70 $ (116) $ 236,949 
Contractual Maturities Of Marketable Securities	  As of March 31, 2017 Amortized Cost Fair Value   Due in one year or less $ 144,581 $ 144,547  Due after one year through three years 95,382 95,386  $ 239,963 $ 239,933 

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2017
Inventories [Abstract]
Schedule Of Components Of Inventories	  March 31, December 31,  2017 2016   Raw materials $ 28,232 $ 27,561  Work-in-process 18,804 14,998  Finished goods 125,147 115,475  Inventories $ 172,183 $ 158,034 

Other Current and Long-Term A34

Other Current and Long-Term Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Other Current and Long-Term Assets [Abstract]
Schedule Of Other Current Assets	  March 31, December 31,  2017 2016   Prepaid expenses $ 25,330 $ 25,746  Taxes receivable 20,217 27,672  Customer acquisition costs, net 19,364 18,085  Other assets 15,800 19,703  Other current assets $ 80,711 $ 91,206 
Schedule Of Other Noncurrent Assets	  March 31, December 31,  2017 2016   Investment in long-term product supply arrangements $ 10,170 $ 10,978  Customer acquisition costs, net 54,602 50,309  Other assets 35,344 36,321  Deferred income taxes 5,867 5,707  Other long-term assets $ 105,983 $ 103,315 

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities [Abstract]
Schedule Of Accrued Liabilities	  March 31, December 31,  2017 2016   Accrued expenses $ 55,545 $ 71,984  Accrued employee compensation and related expenses 49,249 91,113  Accrued taxes 21,272 23,973  Accrued customer programs 48,697 49,061  Accrued liabilities $ 174,763 $ 236,131 

Repurchases Of Common Stock (Ta

Repurchases Of Common Stock (Tables)	3 Months Ended
	Mar. 31, 2017
Repurchases Of Common Stock [Abstract]
Schedule Of Common Stock Repurchases	  For the Three Months Ended  March 31,  2017 2016   Shares repurchased in the open market 390 708  Shares acquired through employee surrender for statutory tax withholding 52 52  Total shares repurchased 442 760   Cost of shares repurchased in the open market $ 50,744 $ 49,715  Cost of shares for employee surrenders 7,303 3,529  Total cost of shares $ 58,047 $ 53,244   Average cost per share - open market repurchase $ 130.12 $ 70.21  Average cost per share - employee surrenders $ 141.09 $ 67.96  Average cost per share - total $ 131.41 $ 70.06

Accumulated Other Comprehensi37

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2017
Accumulated Other Comprehensive Income [Abstract]
Schedule Of Accumulated Other Comprehensive Income	  For the Three Months Ended March 31, 2017 Unrealized Gain (Loss) on Investments, Net of Tax Unrealized Gain (Loss) on Derivative Instruments, Net of Tax Unrealized Gain (Loss) on Net Investment Hedge, Net of Tax Cumulative Translation Adjustment Total   Balance as of December 31, 2016 $ 20 $ 4,916 $ 4,036 $ (52,025) $ (43,053)  Other comprehensive (loss) income before reclassifications (39) (1,534) (1,093) 8,014 5,348  Gains reclassified from accumulated other comprehensive income - (674) - - (674)  Balance as of March 31, 2017 $ (19) $ 2,708 $ 2,943 $ (44,011) $ (38,379) 
Summary Of Reclassifications Out Of Accumulated Other Comprehensive Income	  Details about AOCI Components Affected Line Item in the Statement of Operations Amounts Reclassified from AOCI For the Three Months Ended March 31,  2017 2016  Gains (losses) on derivative instruments classified as cash flow hedges included in net income:  Foreign currency exchange contracts Cost of revenue $ 1,075 $ 809  Interest rate swaps Interest expense - (210)  Total gains before tax 1,075 599  Tax expense 401 170  Gains, net of tax $ 674 $ 429  

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share	  For the Three Months Ended  March 31,  2017 2016   Shares outstanding for basic earnings per share 88,117 89,924   Shares outstanding for diluted earnings per share:  Shares outstanding for basic earnings per share 88,117 89,924  Dilutive effect of share-based payment awards 1,877 914  89,994 90,838 
Schedule Of Number Of Anti-Dilutive Stock Options	  For the Three Months Ended  March 31,  2017 2016   Weighted average number of shares underlying anti-dilutive options 182 1,044   Weighted average number of shares underlying anti-dilutive restricted stock units 47 - 

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Summary Of Segment Performance	   For the Three Months Ended March 31,  CAG Water LPD Other Unallocated Amounts Consolidated Total  2017  Revenue $ 403,227 $ 25,077 $ 29,317 $ 4,400 $ - $ 462,021   Income (loss) from operations $ 79,855 $ 10,263 $ 3,802 $ 393 $ (2,070) $ 92,243  Interest expense, net (7,506)  Income before provision for income taxes 84,737  Provision for income taxes 15,679  Net income 69,058  Less: Net income attributable to noncontrolling interest 39  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 69,019   2016  Revenue $ 357,639 $ 23,552 $ 30,856 $ 5,503 $ - $ 417,550   Income (loss) from operations $ 61,378 $ 9,679 $ 4,570 $ (837) $ (997) $ 73,793  Interest expense, net (7,484)  Income before provision for income taxes 66,309  Provision for income taxes 20,284  Net income 46,025  Less: Net income attributable to noncontrolling interest 6  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 46,019 
Summary Of Revenue By Product And Service Category	  For the Three Months Ended  March 31,  2017 2016  CAG segment revenue:  CAG Diagnostics recurring revenue: $ 346,680 $ 305,841  IDEXX VetLab consumables 123,553 107,969  Rapid assay products 47,895 43,086  Reference laboratory diagnostic and consulting services 159,069 140,708  CAG Diagnostics service and accessories 16,163 14,078  CAG Diagnostics capital - instruments 26,183 22,643  Veterinary software, services and diagnostic imaging systems 30,364 29,155  CAG segment revenue 403,227 357,639   Water segment revenue 25,077 23,552  LPD segment revenue 29,317 30,856  Other segment revenue 4,400 5,503  Total revenue $ 462,021 $ 417,550 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Measurements [Abstract]
Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis	  Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of March 31, 2017 (Level 1) (Level 2) (Level 3) March 31, 2017   Assets  Money market funds (1) $ 26,523 $ - $ - $ 26,523  Certificates of deposit (1) - 2,001 - 2,001  Commercial paper (1) - 2,998 - 2,998   Marketable Securities  Corporate bonds - 120,893 - 120,893  Certificates of deposit - 43,198 - 43,198  Asset backed securities - 37,600 - 37,600  Commercial paper - 17,013 - 17,013  U.S. government bonds - 16,630 - 16,630  Agency bonds - 4,599 - 4,599  Total marketable securities - 239,933 - 239,933   Equity mutual funds (2) 2,196 - - 2,196  Foreign currency exchange contracts (3) - 5,445 - 5,445  Liabilities  Foreign currency exchange contracts (3) - 1,344 - 1,344  Deferred compensation (4) 2,196 - - 2,196     Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of December 31, 2016 (Level 1) (Level 2) (Level 3) December 31, 2016   Assets  Money market funds (1) $ 34,208 $ - $ - $ 34,208  Certificates of deposit (1) - 1,500 - 1,500  Commercial paper (1) - 898 - 898   Marketable Securities  Corporate bonds - 130,771 - 130,771  Certificates of deposit - 40,400 - 40,400  Asset backed securities - 27,315 - 27,315  Commercial paper - 20,228 - 20,228  U.S. government bonds - 12,231 - 12,231  Agency bonds - 4,604 - 4,604  Municipal bonds - 1,400 - 1,400  Total marketable securities - 236,949 - 236,949   Equity mutual funds (2) 2,182 - - 2,182  Foreign currency exchange contracts (3) - 8,926 - 8,926  Liabilities  Foreign currency exchange contracts (3) - 1,081 - 1,081  Deferred compensation (4) 2,182 - - 2,182 _____________ (1) Money market funds, certificates of deposit and commercial paper with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of March 3 1 , 201 7 and December 31, 201 6 consisted of demand deposits. Commercial paper and certificates of deposit with an original maturity of over ninety days are included within marketable securities. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets. See footnote (4) below for a discussion of the related deferred compensation liability. (3) Foreign currency exchange contracts are included within other current assets; other long-term assets; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date. (4) A deferred compensation plan assumed as part of a previous business combination is included within accrued liabilities and other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in footnote (2) above.

Hedging Instruments (Tables)

Hedging Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Derivative [Line Items]
Gain/(Loss) Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)	  Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion)  For the Three Months Ended  March 31,  Derivative instruments 2017 2016   Cash flow hedging derivatives:  Foreign currency exchange contracts, net of tax $ (2,208) $ (3,806)  Interest rate swaps, net of tax - 111  Total cash flow hedges $ (2,208) $ (3,695) 
Assets [Member]
Derivative [Line Items]
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	  Hedging Assets  March 31, December 31,  2017 2016   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Other current assets $ 4,937 $ 8,926  Foreign currency exchange contracts Other long-term assets 508 -  Total derivative instruments presented as cash flow hedges on the balance sheet 5,445 8,926  Gross amounts subject to master netting arrangements not offset on the balance sheet 1,082 679  Net amount $ 4,363 $ 8,247 
Liabilities [Member]
Derivative [Line Items]
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	  Hedging Liabilities  March 31, December 31,  2017 2016   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Accrued liabilities $ 1,174 $ 1,081  Foreign currency exchange contracts Other long-term liabilities 170 -  Total derivative instruments presented as cash flow hedges on the balance sheet 1,344 1,081  Foreign currency borrowings designated as net investment hedge on the balance sheet Long-term debt 95,406 93,664  Total hedging instruments presented on the balance sheet 96,750 94,745  Gross amounts subject to master netting arrangements not offset on the balance sheet 1,082 679  Net amount $ 95,668 $ 94,066 

Basis Of Presentation And Pri42

Basis Of Presentation And Principles Of Consolidation (Details)	3 Months Ended
	Mar. 31, 2017USD ($)
Revolving Credit Facility [Member]
Borrowing capacity	$ 850,000,000
Debt instrument, term	5 years
Senior Notes [Member]
Debt instrument, face amount	$ 600,000,000

Accounting Policies (Narrative)

Accounting Policies (Narrative) (Details) - $ / shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accounting Policies [Abstract]
Diluted	$ 0.77	$ 0.51

Accounting Policies (Summary Of

Accounting Policies (Summary Of The Most Significant Impacts Of The New Accounting Guidance) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Increase in operating activities	$ 31,274	$ 26,990
Decrease in financing activities	(1,313)	2,562
Accounting Standards Update 2016-09 [Member]
Effective Income Tax Rate Reconciliation, Deduction, Amount	$ 11,200
Weighted Average Number Diluted Shares Outstanding Adjustment	450,000
Accounting Standards Update 2016-09 [Member] | Tax Benefits Related To Share-based Payments At Settlement Classified As Operating Cash Flows Instead Of Financing Cash Flows [Member]
Increase in operating activities	$ 11,200
Decrease in financing activities	11,200
Accounting Standards Update 2016-09 [Member] | Cash Payments To Tax Authorities For Shares Withheld To Meet Tax Withholding Requirements On Restricted Stock Units Are Classified As Financing Cash Flow Instead Of Operating Cash Flow [Member]
Increase in operating activities	7,300	3,800
Decrease in financing activities	$ 7,300	$ 3,800

Accounting Policies (table) (De

Accounting Policies (table) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accounting Policies [Abstract]
Net cash provided by operating activities	$ 31,274	$ 26,990
Net cash provided (used) by financing activities	$ 1,313	$ (2,562)

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-Based Compensation [Abstract]
Fair value of share-based compensation awards, granted	$ 27.9	$ 24
Unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding	$ 58
Weighted average recognition period for unrecognized compensation expense, in years	2 years 3 months 18 days

Share-Based Compensation (Sched

Share-Based Compensation (Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards) (Details) - $ / shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-Based Compensation [Abstract]
Share price at grant	$ 141.60	$ 67.85
Expected stock price volatility	26.00%	25.00%
Expected term, in years	5 years 9 months 18 days	5 years 8 months 12 days
Risk-free interest rate	2.00%	1.20%
Weighted average fair value of options granted	$ 40.51	$ 17.54

Marketable Securities (Amortize

Marketable Securities (Amortized Cost And Fair Value Of Marketable Securities) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 239,963	$ 236,995
Gross Unrealized Gains	83	70
Gross Unrealized Losses	(113)	(116)
Fair Value	239,933	236,949
Marketable securities that we consider to be other-than-temporarily impaired	0
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	120,898	130,833
Gross Unrealized Gains	76	40
Gross Unrealized Losses	(81)	(102)
Fair Value	120,893	130,771
Certificates Of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	43,198	40,400
Fair Value	43,198	40,400
Asset-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	37,610	27,290
Gross Unrealized Gains	6	25
Gross Unrealized Losses	(16)
Fair Value	37,600	27,315
Commercial Paper - Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	17,013	20,228
Fair Value	17,013	20,228
U.S. Government Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	16,644	12,244
Gross Unrealized Gains	1	1
Gross Unrealized Losses	(15)	(14)
Fair Value	16,630	12,231
Agency Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	4,600	4,600
Gross Unrealized Gains		4
Gross Unrealized Losses	(1)
Fair Value	$ 4,599	4,604
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		1,400
Fair Value		$ 1,400

Marketable Securities (Contract

Marketable Securities (Contractual Maturities Of Marketable Securities) (Details) $ in Thousands	Mar. 31, 2017USD ($)
Marketable Securities [Abstract]
Due in one year or less, Amortized Cost	$ 144,581
Due after one year through three years, Amortized Cost	95,382
Total marketable securities, Amortized Cost	239,963
Due in one year or less, Fair Value	144,547
Due after one year through three years, Fair Value	95,386
Total marketable securities, Fair Value	$ 239,933

Inventories (Schedule Of Compon

Inventories (Schedule Of Components Of Inventories) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventories [Abstract]
Raw materials	$ 28,232	$ 27,561
Work-in-process	18,804	14,998
Finished goods	125,147	115,475
Inventories	$ 172,183	$ 158,034

Goodwil And Intangible Assets,

Goodwil And Intangible Assets, Net (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)entity	Mar. 31, 2016USD ($)
Impairment charge		$ 2.2
Reference Laboratory In Austria [Member]
Number of Businesses Acquired | entity	1
Business Combination, Consideration Transferred	$ 1.6

Other Current and Long-Term A52

Other Current and Long-Term Assets (Schedule Of Other Current Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Other Current and Long-Term Assets [Abstract]
Prepaid expenses	$ 25,330	$ 25,746
Taxes receivable	20,217	27,672
Customer acquisition costs, net	19,364	18,085
Other assets	15,800	19,703
Other current assets	$ 80,711	$ 91,206

Other Current and Long-Term A53

Other Current and Long-Term Assets (Schedule Of Other Noncurrent Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Other Current and Long-Term Assets [Abstract]
Investment in long-term product supply arrangements	$ 10,170	$ 10,978
Customer acquisition costs, net	54,602	50,309
Other assets	35,344	36,321
Deferred income taxes	5,867	5,707
Other long-term assets	$ 105,983	$ 103,315

Accrued Liabilities (Schedule O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accrued Liabilities [Abstract]
Accrued expenses	$ 55,545	$ 71,984
Accrued employee compensation and related expenses	49,249	91,113
Accrued taxes	21,272	23,973
Accrued customer programs	48,697	49,061
Accrued liabilities	$ 174,763	$ 236,131

Repurchases Of Common Stock (De

Repurchases Of Common Stock (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Repurchases Of Common Stock [Abstract]
Shares repurchased in the open market	390	708
Shares acquired through employee surrender for statutory tax withholding	52	52
Total shares repurchased	442	760
Cost of shares repurchased in the open market	$ 50,744	$ 49,715
Cost of shares for employee surrenders	7,303	3,529
Total cost of shares	$ 58,047	$ 53,244
Average cost per share - open market repurchase	$ 130.12	$ 70.21
Average cost per share - employee surrenders	141.09	67.96
Average cost per share - total	$ 131.41	$ 70.06

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Taxes [Abstract]
Effective Tax Rate	18.50%	30.60%
Effective Income Tax Rate Reconciliation, Deduction, Dividend, Percent	13.00%

Accumulated Other Comprehensi57

Accumulated Other Comprehensive Income (Schedule Of Accumulated Other Comprehensive Income) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Balance, value	$ (108,213)
Balance, value	(73,912)
AOCI Including Portion Attributable to Noncontrolling Interest [Member]
Balance, value	(43,053)
Other comprehensive (loss) income before reclassifications	5,348
Gains reclassified from accumulated other comprehensive income	(674)
Balance, value	(38,379)
Unrealized Gain (Loss) on Investments, Net of Tax [Member]
Balance, value	20
Other comprehensive (loss) income before reclassifications	(39)
Balance, value	(19)
Unrealized Gain (Loss) on Derivative Instruments, Net of Tax [Member]
Balance, value	4,916
Other comprehensive (loss) income before reclassifications	(1,534)
Gains reclassified from accumulated other comprehensive income	(674)
Balance, value	2,708
Unrealized Gain (Loss) on Net Investment Hedge, Net of Tax [Member]
Balance, value	4,036
Other comprehensive (loss) income before reclassifications	(1,093)
Balance, value	2,943
Cumulative Translation Adjustment [Member]
Balance, value	(52,025)
Other comprehensive (loss) income before reclassifications	8,014
Balance, value	$ (44,011)

Accumulated Other Comprehensi58

Accumulated Other Comprehensive Income (Schedule of Reclassifications out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Tax expense (benefit)	$ 15,679	$ 20,284
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	1,075	599
Tax expense (benefit)	401	170
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	674	429
Foreign Currency Exchange Contracts [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	$ 1,075	809
Interest Rate Swaps [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax		$ (210)

Earnings Per Share (Schedule Of

Earnings Per Share (Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share) (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
Shares outstanding for basic earnings per share	88,117	89,924
Dilutive effect of share-based payment awards	1,877	914
Shares outstanding for diluted earnings per share	89,994	90,838

Earnings Per Share (Schedule 60

Earnings Per Share (Schedule Of Number Of Anti-Dilutive Stock Options) (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Stock Options [Member]
Antidilutive Securities [Line Items]
Weighted average number of shares underlying anti-dilutive options	182	1,044
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities [Line Items]
Weighted average number of shares underlying anti-dilutive options	47

Segment Reporting (Summary Of S

Segment Reporting (Summary Of Segment Performance) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Revenue	$ 462,021	$ 417,550
Income (loss) from operations	92,243	73,793
Interest expense, net	(7,506)	(7,484)
Income before provision for income taxes	84,737	66,309
Provision for income taxes	15,679	20,284
Net income	69,058	46,025
Less: Net income attributable to noncontrolling interest	39	6
Net income attributable to IDEXX Laboratories, Inc. stockholders	69,019	46,019
Depreciation and amortization	20,307	18,546
Expenditures for long-lived assets	23,647	21,906
CAG Segment [Member]
Segment Reporting Information [Line Items]
Revenue	403,227	357,639
Income (loss) from operations	79,855	61,378
Water Segment [Member]
Segment Reporting Information [Line Items]
Revenue	25,077	23,552
Income (loss) from operations	10,263	9,679
LPD Segment [Member]
Segment Reporting Information [Line Items]
Revenue	29,317	30,856
Income (loss) from operations	3,802	4,570
Other Segment [Member]
Segment Reporting Information [Line Items]
Revenue	4,400	5,503
Income (loss) from operations	393	(837)
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Income (loss) from operations	$ (2,070)	$ (997)

Segment Reporting (Summary Of R

Segment Reporting (Summary Of Revenue By Product And Service Category) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Revenue	$ 462,021	$ 417,550
CAG Diagnostics Recurring Revenue [Member]
Segment Reporting Information [Line Items]
Revenue	346,680	305,841
IDEXX Vetlab Consumables [Member]
Segment Reporting Information [Line Items]
Revenue	123,553	107,969
IDEXX VetLab Service and Accessories [Member]
Segment Reporting Information [Line Items]
Revenue	47,895	43,086
Rapid Assay Products [Member]
Segment Reporting Information [Line Items]
Revenue	159,069	140,708
Reference Laboratory Diagnostic And Consulting Services [Member]
Segment Reporting Information [Line Items]
Revenue	16,163	14,078
CAG Diagnostic Capital - Instruments [Member]
Segment Reporting Information [Line Items]
Revenue	26,183	22,643
Veterinary Software, Services and Diagnostic Imaging Systems [Member]
Segment Reporting Information [Line Items]
Revenue	30,364	29,155
CAG Segment [Member]
Segment Reporting Information [Line Items]
Revenue	403,227	357,639
Water Segment [Member]
Segment Reporting Information [Line Items]
Revenue	25,077	23,552
LPD Segment [Member]
Segment Reporting Information [Line Items]
Revenue	29,317	30,856
Other Segment [Member]
Segment Reporting Information [Line Items]
Revenue	$ 4,400	$ 5,503

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Carrying value of long-term debt	$ 594,868	$ 593,110
Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt, Fair Value	$ 611,000	$ 609,500

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	$ 239,933	$ 236,949
Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	120,893	130,771
Certificates Of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	43,198	40,400
Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	37,600	27,315
Commercial Paper - Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	17,013	20,228
U.S. Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	16,630	12,231
Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities		1,400
Measured At Fair Value On Recurring Basis [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	239,933	236,949
Measured At Fair Value On Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	239,933	236,949
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,196	2,182
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,196	2,182
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	5,445	8,926
Fair value of Liabilities	1,344	1,081
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	5,445	8,926
Fair value of Liabilities	1,344	1,081
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	2,196	2,182
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	2,196	2,182
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	26,523	34,208
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	26,523	34,208
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit - Maturity Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,001	1,500
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit - Maturity Less Than 90 Days [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,001	1,500
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,998	898
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,998	898
Measured At Fair Value On Recurring Basis [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	120,893	130,771
Measured At Fair Value On Recurring Basis [Member] | Corporate Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	120,893	130,771
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	43,198	40,400
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	43,198	40,400
Measured At Fair Value On Recurring Basis [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	37,600	27,315
Measured At Fair Value On Recurring Basis [Member] | Asset-backed Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	37,600	27,315
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper - Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	17,013	20,228
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper - Marketable Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	17,013	20,228
Measured At Fair Value On Recurring Basis [Member] | U.S. Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	16,630	12,231
Measured At Fair Value On Recurring Basis [Member] | U.S. Government Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	16,630	12,231
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds- Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	4,599	4,604
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds- Marketable Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	$ 4,599	4,604
Measured At Fair Value On Recurring Basis [Member] | Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities		1,400
Measured At Fair Value On Recurring Basis [Member] | Municipal Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities		$ 1,400

Hedging Instruments (Narrative)

Hedging Instruments (Narrative) (Details) $ in Thousands, € in Millions	3 Months Ended
	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2017EUR (€)	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Derivative [Line Items]
Estimated net amount of gains expected to be reclassified out of accumulated other comprehensive income and into earnings within next 12 months	$ 2,500
Cash Flow Hedge, hedge percentage of estimated exposure from intercompany products purchases and sales	85.00%
General duration of foreign currency exchange contracts	24 months
Notional Amount of Foreign Currency Exchange Contracts				$ 203,500	$ 175,900
Unrealized (loss) gain on net investment hedge	$ (1,093)	$ 2,224
Series C Senior Note [Member]
Derivative [Line Items]
Debt instrument, face amount | €			€ 88.9
Stated interest rate			1.785%	1.785%
Interest Rate Swap Effective On March 30, 2012 [Member]
Derivative [Line Items]
Fixed portion of interest rate associated with interest rate swap			1.36%	1.36%
Credit Facility borrowings hedged				$ 40,000
Interest Rate Swap Effective On March 28, 2013 [Member]
Derivative [Line Items]
Fixed portion of interest rate associated with interest rate swap			1.64%	1.64%
Credit Facility borrowings hedged				$ 40,000

Hedging Instruments (Schedule O

Hedging Instruments (Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	$ 96,750	$ 94,745
Hedging Liabilities, Gross amounts subject to master netting arrangements not offset on the balance sheet	1,082	679
Hedging Liabilities, Net amount	95,668	94,066
Cash Flow Hedges [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	1,344	1,081
Derivatives Designated As Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Gross amounts subject to master netting arrangements not offset on the balance sheet	1,082	679
Hedging Assets, Net amount	4,363	8,247
Derivatives Designated As Hedging Instruments [Member] | Cash Flow Hedges [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	5,445	8,926
Foreign Currency Exchange Contracts [Member] | Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	1,174	1,081
Foreign Currency Exchange Contracts [Member] | Other Long-Term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	170
Foreign Currency Exchange Contracts [Member] | Derivatives Designated As Hedging Instruments [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	4,937	8,926
Foreign Currency Exchange Contracts [Member] | Derivatives Designated As Hedging Instruments [Member] | Other Long-Term Assets, Net [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	508
Foreign Currency Borrowings Designated As Net Investment Hedge On The Balance Sheet [Member] | Long-term Debt [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	$ 95,406	$ 93,664

Hedging Instruments ((Loss) Gai

Hedging Instruments ((Loss) Gain Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)) (Details) - Derivatives Designated As Hedging Instruments [Member] - Cash Flow Hedges [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion), Net of Tax	$ (2,208)	$ (3,695)
Foreign Currency Exchange Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion), Net of Tax	$ (2,208)	(3,806)
Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion), Net of Tax		$ 111